Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a notable stock increase today, contrasting with the decline of the China Shanghai Composite. Despite a challenging year with a significant decline, the company has shown resilience over three years. Financial metrics indicate a strong market cap and recent positive sales results, but challenges remain.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a rise in its stock price today, contrasting with the broader market's performance. Despite recent gains, the company has faced challenges, including a decline over the past week and month, and reports losses alongside a negative net worth, indicating financial difficulties.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline, contrasting with the broader market's performance. Despite reporting positive quarterly results, the company faces financial challenges, including a low return on capital and negative net worth, raising concerns about its long-term growth potential in the pharmaceuticals sector.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with gains in the China Shanghai Composite. The company has struggled over the past year, facing challenges such as a low return on capital employed and a negative net worth, despite reporting positive quarterly results.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a notable intraday gain, contrasting with a decline in the China Shanghai Composite. Despite a challenging year with negative returns, the company has shown resilience year-to-date. Key metrics indicate a large market capitalization and positive quarterly results, though risks remain regarding long-term growth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, reflecting ongoing market challenges. Despite reporting positive quarterly results, the company struggles with low returns and negative net worth. Its one-year performance remains negative, contrasting with the broader market's positive trends. The company's market capitalization is CNY 27,093 million.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a decline in stock price today, contrasting with the overall market's modest gain. Despite recent positive quarterly results and improved operational efficiency, the company has underperformed over the past year, facing challenges such as a negative net worth and low return on capital employed.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has experienced notable stock performance, contrasting with a decline in the broader market. The company has shown consistent quarterly growth in net sales and reduced raw material costs, although it faces challenges such as a low return on capital and negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has recently adjusted its evaluation, reflecting its performance metrics and market position. The company reported net sales of CNY 217.79 million for the quarter ending September 2025, alongside a decrease in raw material costs. However, challenges remain, including a low return on capital employed.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant increase in its stock price today, contrasting with the broader market's performance. Despite recent gains, the company has struggled over the past year, reporting losses and a negative net worth, though it has achieved positive sales results for four consecutive quarters.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. experienced a notable intraday gain, contrasting with a decline in the broader market. Despite positive quarterly results, the company has struggled over the past year, facing challenges such as low return on capital and a negative net worth, indicating potential financial risks.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a notable increase on March 16, 2026, contrasting with a slight decline in the China Shanghai Composite. Despite recent gains, the company has faced challenges over the past year, underperforming the broader market, while maintaining a large-cap status in the pharmaceuticals sector.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a decline in stock performance today, contrasting with the minor decrease in the China Shanghai Composite. Despite recent gains over the past week, the company has struggled year-to-date and over the past year, facing challenges such as low returns and negative net worth.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a notable increase in stock performance on March 10, 2026, reaching an intraday high. The company reported positive results over the last four quarters, with net sales of CNY 217.79 million and improved operational efficiency, despite facing longer-term challenges.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant rise in its stock today, contrasting with the modest gain of the China Shanghai Composite. However, the company has struggled over the past year, with negative returns and financial challenges, despite reporting positive quarterly results and a substantial market capitalization.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. The company has struggled over the past year, with a notable year-to-date drop and low return on capital employed, despite reporting positive results in recent quarters.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. faced a notable stock decline today, contrasting with the broader market. While the company has shown a strong annual return, it struggles with management efficiency and consistent losses, raising concerns about its sustainability. Nonetheless, it reported positive results for the last four quarters.